Novonesis and DUT join Bill Gates-backed CO2-to-protein project
The effort is part of the larger Acetate Consortium, which receives funding from Bill Gates’ and Novo Nordisk’s foundations, and aims to produce CO2-derived acetate. Most microbes naturally thrive on glucose but struggle to make efficient use of acetic acid derived from captured carbon. That limitation is the key bottleneck in the CO₂‑to‑protein process the new partnership aims to overcome.
“This collaboration shows what it takes to make impact,” Jochen Förster, director of the Bright Biofoundry, tells Green Queen. “Aligned partners, complementary expertise, and the courage to work through complexity together. We look forward to continuing the work and strengthening the collaboration in the years ahead.”
Category: Chemicals & Materials
